Literature DB >> 2186834

Theophylline in the management of airflow obstruction. 2. Difficult drugs to use, few clinical indications.

I D Johnston1.   

Abstract

The narrow therapeutic index, potential toxicity, and need to monitor plasma concentrations make theophyllines difficult to use. Other drugs provide comparable or better bronchodilator and prophylactic efficacy. In asthma theophyllines should be considered for chronic stable asthma when treatment with optimal doses of inhaled steroids and bronchodilators fails to provide adequate control; for nocturnal asthma; and for prophylaxis and relief of symptoms in children and adults when inhaled treatment cannot be given. In general, theophyllines cannot be recommended for chronic airflow obstruction. A trial of theophylline is reasonable in individual patients whose symptoms remain troublesome despite a trial of steroids and optimal doses of inhaled bronchodilators.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186834      PMCID: PMC1662649          DOI: 10.1136/bmj.300.6729.929

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  20 in total

1.  Relationship between serum theophylline levels and pulmonary function before and after inhaled beta-agonist in "stable" asthmatics.

Authors:  J J Klein; M S Lefkowitz; S L Spector; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1983-04

2.  Single-dose slow-release aminophylline at night prevents nocturnal asthma.

Authors:  P J Barnes; A P Greening; L Neville; J Timmers; G W Poole
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

3.  Inhibition of exercise-induced asthma by theophylline.

Authors:  E F Ellis
Journal:  J Allergy Clin Immunol       Date:  1984-05       Impact factor: 10.793

4.  Sustained release oral aminophylline in patients with airflow obstruction.

Authors:  A P Greening; E Baillie; H R Gribbin; N B Pride
Journal:  Thorax       Date:  1981-04       Impact factor: 9.139

5.  Intravenous salbutamol and aminophylline in asthma: a search for synergy.

Authors:  P D Handslip; A M Dart; B H Davies
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

Review 6.  Theophylline reassessed.

Authors:  M Bukowskyj; K Nakatsu; P W Munt
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

7.  Theophylline and aerosolized terbutaline in the treatment of bronchial asthma. Double-blind comparison of optimal doses.

Authors:  J A Smith; R W Weber; H S Nelson
Journal:  Chest       Date:  1980-12       Impact factor: 9.410

8.  Theophylline prescribing, serum concentrations, and toxicity.

Authors:  A A Woodcock; M A Johnson; D M Geddes
Journal:  Lancet       Date:  1983-09-10       Impact factor: 79.321

9.  Dose response relation to oral theophylline in severe chronic obstructive airways disease.

Authors:  H Chrystyn; B A Mulley; M D Peake
Journal:  BMJ       Date:  1988-12-10

10.  A comparison of oral choline theophyllinate and beclomethasone in severe perennial asthma in children.

Authors:  A T Edmunds; S McKenzie; E Baillie; M Tooley; S Godfrey
Journal:  Br J Dis Chest       Date:  1979-04
View more
  7 in total

Review 1.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.

Authors:  G Van den Brink; C W Bollen; O E Van de Wall; L J Hoeve; A J Porsius
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

3.  Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?

Authors:  P A Bardsley
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

4.  Intravenous aminophylline increases the degree of saturation of urine with calcium phosphate and struvite.

Authors:  A Siwińska; J Głuszek; J Maciejewski; D Musialik
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

5.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

Authors:  S E McKay; C A Howie; A H Thomson; B Whiting; G J Addis
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

7.  Computer assisted design of a theophylline dosing regimen in acute bronchospasm: serum concentrations and clinical outcome.

Authors:  D Verner; H Seligmann; S Platt; S Dany; S Almog; L Zulty; H Halkin; D Ezra
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.